RBx11160 Phase II Dose Ranging Study RBx/MMV05-06

PHASE2CompletedINTERVENTIONAL
Enrollment

255

Participants

Timeline

Start Date

June 30, 2006

Study Completion Date

January 31, 2007

Conditions
Plasmodium Falciparum Malaria
Interventions
DRUG

Treatment with 3 dose groups of RBx11160 over 7 days

Trial Locations (4)

10400

Faculty of Tropical Medicine, 420/6 Rajavithee Road, Bangkok

769 002

Field Station Malaria Reseach Centre (Indian Council of Medical Research), Rourkela

Unknown

Public Health Care Center, Kivunge

District Hospital Bagamayo, Dar es Salaam

All Listed Sponsors
collaborator

Ranbaxy Laboratories Limited

INDUSTRY

collaborator

Swiss Tropical & Public Health Institute

OTHER

lead

Medicines for Malaria Venture

OTHER

NCT00362050 - RBx11160 Phase II Dose Ranging Study RBx/MMV05-06 | Biotech Hunter | Biotech Hunter